About 5 results found for searched term "AT-406" (0.174 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M2026 | AT-406 | IAP |
| SM-406; Xevinapant; Debio 1143 | ||
| Xevinapant (Debio1143,AT-406, SM-406) is a potentially first-in-class, highly potent oral antagonist of inhibitor of apoptosis protein (IAP), which not only promotes cancer cell death by inhibiting IAP, but also It can enhance the anti-tumor immune response by inhibiting IAP. | ||
| M13549 | Xevinapant hydrochloride | IAP |
| AT-406 hydrochloride; Debio 1143 hydrochloride; SM-406 hydrochloride | ||
| Xevinapant (AT-406) hydrochloride is a potent and orally bioavailable Smac mimetic and an antagonist of the inhibitor of apoptosis proteins (IAPs). | ||
| M7534 | SSR240612 | Bradykinin Receptor |
| Treatment with the kinin B1 receptor antagonist, SSR240612, provided a protective effect against organ damage by interfering with multiple target functions, including the suppression of B1R-induced inflammation and platelet aggregation. | ||
| M14917 | Fostamatinib disodium hexahydrate | Syk |
| R788 disodium hexahydrate | ||
| Fostamatinib (R788) disodium hexahydrate is the oral prodrug of the active compound R406. | ||
| M27952 | L-670596 | Prostaglandin Receptor |
| L-670596 is an orally active and selective thrombsxane A2 receptor/prostaglandin receptor antagonist. L-670596 inhibits arachidonic acid and U-44069 induced bronchoconstriction in the guinea pig. L-670596 also inhibits the aggregation of human platelet rich plasma induced by U-44069. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
